Information Provided By: 
Fly News Breaks for May 3, 2017
GNMK
May 3, 2017 | 08:32 EDT
Canaccord analyst Mark Massaro noted GenMark delivered another good quarter and, more importantly, expects FDA approval on the ePlex system and the Respiratory Panel very soon. The analyst believes the company may be a few weeks away from the approval and a strong commercial launch. Massaro raised his estimates and reiterated his Buy rating while raising his price target to $17 from $14 on GenMark shares.
News For GNMK From the Last 2 Days
There are no results for your query GNMK
